Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units

Pfizer CEO Albert Bourla acquired 24 phantom stock units under a deferred compensation plan, increasing his beneficial ownership to 743,147 units.

Summary

• Albert Bourla, Chairman & CEO of Pfizer Inc., acquired 24 phantom stock units on December 31, 2025.
• These units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Each unit represents one phantom share of common stock.
• The phantom stock units are settled in cash following Bourla's separation from service and can be transferred into an alternative investment account at any time.
• The price of the derivative security for this transaction was $24.9 per unit.
• Following this reported transaction, Albert Bourla beneficially owns a total of 743,147 phantom stock units.

Sentiment

Score: 6

Explanation: The event is neutral to slightly positive, indicating continued executive participation in compensation plans, which is a routine governance matter and not a significant market-moving event.

Positives

• The acquisition of phantom stock units demonstrates continued participation by the CEO in the company's long-term incentive and deferred compensation plans, aligning executive interests with shareholder value over time.

Future Outlook

The phantom stock units are designed to be settled in cash following the reporting person's separation from service, indicating a long-term incentive structure tied to executive retention and future performance.

Industry Context

This transaction reflects a common practice in executive compensation within large pharmaceutical companies, where deferred compensation and long-term incentives, often in the form of phantom stock or similar equity-linked instruments, are used to align executive interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of phantom stock units as part of a nonfunded deferred compensation and supplemental savings plan is a standard executive compensation mechanism across the pharmaceutical industry and other large corporations.
• While specific comparable companies or projects are not detailed in the filing, this type of incentive structure is consistent with practices at peers like Johnson & Johnson, Merck, and Bristol Myers Squibb, which also utilize various forms of long-term equity or equity-linked compensation for their senior executives to encourage retention and performance alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor positive impact as it indicates continued executive alignment with long-term company performance through participation in compensation plans.
• Employees: No direct impact mentioned.

Next Steps

• The phantom stock units will be settled in cash following Albert Bourla's separation from service.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by Pfizer's CEO as part of a deferred compensation plan. It does not introduce new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a standard executive compensation event and does not alter the fundamental investment thesis for Pfizer.

Keywords

Pfizer, PFE, Albert Bourla, Form 4, Insider Transaction, Phantom Stock Units, Deferred Compensation, CEO, Executive Compensation